Introduction
============

Rearrangements at 8q24 have been reported in up to 47% of myeloma patients by a combination of fluorescence *in situ* hybridization (FISH), spectral karyotyping and classical cytogenetics.^[@bib1]^ In presenting myeloma this frequency is lower, with abnormalities of 8q reported in 15% of cases using mapping arrays and FISH.^[@bib2],\ [@bib3]^ The gene of interest in this region is *MYC*, an oncogene that has a pivotal role in cell growth, proliferation, tumorigenesis and stem cells.^[@bib4]^

The importance of *MYC* activation in myeloma has been shown through the use of the Vk\**MYC* transgenic mouse model, where activation of *MYC* arises through AID-dependent somatic hypermutation during B-cell development, resulting in the onset of myeloma in these mice.^[@bib5]^ *MYC* has also been shown to be activated in the transition from monoclonal gammopathy of undetermined significance to myeloma, implicating it in disease progression.^[@bib6]^ Myeloma cells have been shown to have a dependency on MYC for survival, where inhibition of MYC by small hairpin RNA or small-molecule inhibitors results in cell death indicating that MYC is a promising therapeutic target.^[@bib7]^

The mechanism of *MYC* activation is mainly through secondary translocations involving the immunoglobulin (Ig) loci (*IGH*\>*IGL*\>*IGK*), which juxtapose the strong B-cell enhancers present at these loci and *MYC*, resulting in overexpression of the oncogene.^[@bib8]^ Unlike primary translocations in myeloma, which are often simple reciprocal exchanges of chromosomal material, the rearrangements that result from *MYC* translocations are often complex, involving many partner chromosomes.^[@bib1],\ [@bib8]^ Interestingly, it has been reported that up to 74% of *MYC* rearrangements do not involve an Ig locus^[@bib3]^ leading to the conclusion that other mechanisms of activation may also be important in myeloma. Using FISH, partner chromosomes at 1p13, 1p21--22, 6p21, 6q12--15, 13q14 and 16q22 have been identified, but the specific loci involved have remained elusive.^[@bib3],\ [@bib9],\ [@bib10],\ [@bib11]^

The breakpoints on 8q24 have been mapped in a large number of myeloma cell lines and the majority are found within 1 Mb of *MYC*, but some can be greater than 3 Mb either telomeric or centromeric of the locus.^[@bib8],\ [@bib12],\ [@bib13]^ The loci surrounding *MYC* are *POU5F1B* (centromeric) and *PVT1* (telomeric). *PVT1* is a non-coding RNA that has been shown to be the location of variant t(8;22) breakpoints in Burkitt\'s lymphoma,^[@bib14]^ as well as generating fusion genes with *WWOX* and *NBEA* in myeloma patients with an 8q24 rearrangement.^[@bib13]^

Here, we have used targeted capture followed by massively parallel sequencing to pull down the region surrounding *MYC* in a series of presenting myeloma cases in order to identify any translocations in this area and the mechanism of action involved.

Materials and methods
=====================

Cell selection
--------------

CD138-positive bone marrow plasma cells were selected to a purity \>95% using magnetic assisted cell sorting (Miltenyi Biotech, Bisley, UK). Tumor DNA and RNA were extracted using the AllPrep kit (Qiagen, Manchester, UK). All patients were at presentation and had not received any treatment when the sample was taken.

FISH
----

Probes have been previously published with the addition of the *LPL* (8p22), CEP 8 and *MYC* (8q24.1-24.21) probes (Abbott, Maidenhead, UK).^[@bib15],\ [@bib16],\ [@bib17]^ MYC abnormalities were defined using the t(8;14) fusion probe, *LPL*/CEP 8/*MYC* probes, IGH@ translocations (IGH@ break-apart probe followed by fusion probes for the common partner chromosomes). FISH results were interpreted alongside karyotype data, where available.

Targeted capture of the *MYC* locus
-----------------------------------

A targeted capture system was designed using the SureSelect system (Agilent, Santa Clara, CA, USA) that was based on tiling RNA baits across the *MYC*, *IGH*, *IGK* and *IGL* loci as previously described.^[@bib18]^ The region captured surrounding *MYC* spanned from 127.5--129.8 Mb on chromosome 8, roughly 1 Mb on either side of *MYC*, which is located at 128.75 Mb. This region includes *POU5F1B* and *PVT1,* which are common sites of 8q24 translocations in myeloma.

DNA from 104 samples were assayed using 150 ng of DNA and a modified capture protocol with eight cycles of prehybridization PCR and 11 cycles of posthybridization PCR. Samples were barcoded using Illumina (San Diego, CA, USA) indexes and up to 27 samples were sequenced per lane on a HiSeq2000 generating 76-bp paired-end reads. After base calling and quality control metrics, the raw fastq reads were aligned to the reference human genome (build GRCh37) resulting in a median depth of 289 × per sample after de-duplication for the captured region.

Translocation breakpoints were identified in the sequencing data using DELLY.^[@bib19]^ Breakpoints called using the bioinformatic approach were further filtered based on depth, unique mappability for 76 bp reads, number of supporting reads and whether or not they were detected in non-tumor samples. The coordinates of the breakpoints and superenhancers were compared with randomized data produced using Monte Carlo sampling using the Genomic Hyper Browser.^[@bib20]^

Statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). Discrete data were expressed as frequencies and percentages and were assessed by Fisher\'s exact test or the *χ*^2^-test, as appropriate. Survival curves were plotted using the Kaplan--Meier method. Differences between curves were tested for statistical significance using the log-rank test. A multivariate Cox regression analysis was done to identify factors significantly associated with progression-free survival (PFS) and overall survival (OS), with statistical significance set at *P*\<0.05.

Results
=======

*MYC* rearrangements detected by FISH
-------------------------------------

*MYC* rearrangements were tested for using interphase FISH on CD138^+^ selected plasma cells on patient samples from the UK MRC Myeloma IX trial using a combination of probes for *MYC* (8q24), *LPL* (8p22) and *CEP 8*. Interphase FISH was successful on 751 patients and was interpreted with data from FISH probes for the *IGH* locus and karyotyping. [Table 1](#tbl1){ref-type="table"} shows the frequency of *MYC* abnormalities, split by translocation group in these samples. *MYC* abnormalities were detected in 26% of samples with the most frequent abnormality being gain of the locus, followed by a split probe signal. In 50% (32/63) of those with a split probe signal the *IGH/K/L* locus was identified as the partner. Of the 32 samples with an Ig partner 28 were with the *IGH* locus. In the remaining 50% the partner remained undetermined, but may involve the light chain loci in samples where cytogenetics or karyotyping was unsuccessful or uninformative. *MYC* rearrangements were not associated with any particular primary translocation, but were associated with ISS II (*P*=0.022) or ISS III (*P*=0.0027). There was no negative impact on PFS or OS in patients with a *MYC* abnormality.

*MYC* rearrangements detected by sequence capture
-------------------------------------------------

The presence of unidentified *MYC* partner chromosomes led us to investigate possible partner chromosomes using an alternative technique. We had previously used a DNA capture technique followed by massively parallel sequencing to identify the translocation partner chromosomes to the *IGH/K/L* loci.^[@bib18]^ In this assay we had also captured a region surrounding *MYC* and set out to identify potential partner chromosomes. A region of ∼2 Mb was tiled around the *MYC* locus using RNA baits and used to capture DNA and associated translocations in this region.

We assayed 104 presentation myeloma samples for the presence of *MYC* translocations using the capture assay followed by massively parallel sequencing. The samples consisted of 55 samples from the Myeloma IX trial and an additional 49 samples from the UK Myeloma XI trial, for which FISH results are not available. The samples were categorized according to *IGH* translocation using a combination of FISH,^[@bib15],\ [@bib21]^ gene expression^[@bib22]^ and targeted capture of the *IGH* locus^[@bib18]^ and consisted of a variety of samples with *IGH* translocations and 8q24 rearrangements as shown in [Table 2](#tbl2){ref-type="table"}; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Only three samples analyzed by the capture technique had a split *MYC* locus, as determined by FISH or karyotyping. In these samples the translocation was detected using the capture and was found to be the *IGH* locus in one sample (673; verifying the FISH result) and in the other two samples (29 and 1310) was found to be chromosome 6 (also seen by karyotyping in one sample).

Breakpoints were identified and mapped in 21 samples and are shown in [Figure 1](#fig1){ref-type="fig"}. We identified breakpoints in 10 samples where either FISH or karyotyping failed to identify a translocation, as well as three samples where FISH did identify a translocation and also eight samples for which no FISH data were available. Interestingly, there was an enrichment for t(14;16) and a depletion of t(4;14) and hyperdiploidy associated with an 8q24 breakpoint, [Table 2](#tbl2){ref-type="table"}, which was not seen with FISH alone.

The positions of the breakpoints on 8q24 were spread out over 1.2 Mb. The majority of the breaks were situated telomeric of *PVT1* (51.5%) with 12% within *PVT1*, 15% between *MYC* and *PVT1* and 15% between *POU5F1B* and *MYC*. Of the three samples with breakpoints within *PVT1* two were found to have potential fusion genes, one with *FOXO3* and the other with *LINC00309*.

Nine samples had two breakpoints on 8q24, often with two different chromosome partners. In samples with two breakpoints, the sequencing reads indicate that *MYC* is only involved in one of the breakpoints (that is, only one side of the translocation was captured). The reason for this is not clear and will require long reads to clarify the final genomic rearrangements. Several samples had complex rearrangements resulting in multiple chromosomal segments being joined together, often involving *MYC*, an Ig enhancer and the primary Ig partner oncogene (for example, sample 11/625 that has a t(6;14) and a t(6;8) or sample 12/0404 that has a t(11;14) and a t(8;11)). Details of breakpoints are shown in [Table 3](#tbl3){ref-type="table"}[](#tbl4a){ref-type="table"}[](#tbl4b){ref-type="table"}[](#tbl4c){ref-type="table"}. It is possible that the Ig enhancer is influencing both the target oncogene of the primary translocation (for example, *CCND1* or *CCND3*) and *MYC* through the assembly of a complex t(8;11;14) or t(6;8;14) derivative chromosome.

Superenhancer colocalization with *MYC*
---------------------------------------

A total of 8/21 samples (38%) with *MYC* abnormalities had rearrangements with an Ig locus on the partner chromosome. Ig partner loci are recognized to upregulate expression of the target oncogene and have been shown to have clinical relevance as prognostic markers. Given that the mechanism of upregulation of Ig loci partner oncogenes is through colocalization of active enhancer elements with the oncogene, we examined the remaining samples with rearrangements for the presence of enhancer elements. We used data from two papers in which binding sites of BRD4 and MED1, which occur at transcriptionally active sites, enhancers and superenhancers in MM1.s cells had been annotated using only enhancer sites on the assembled derivative chromosome.^[@bib23],\ [@bib24]^ As expected, the Ig loci breakpoints were typically close to or within an enhancer/superenhancer (minimum distance=0, maximum distance=26 kb) with the exception of *IGKC* breakpoints, which were ∼292 kb from the nearest superenhancer ([Table 3](#tbl3){ref-type="table"}). This discrepancy is likely owing to MM1.s cells being a lambda light chain expresser that do not express a kappa light chain. If a cell line expressing a kappa light chain had been used in the analysis an enhancer may have been detected much closer.

In order to determine whether there was an enrichment of superenhancer sites in the vicinity of *MYC* breakpoints, we used the genomic locations of superenhancers from a variety of the cell types determined in Hnisz *et al.*^[@bib23]^ There was a statistically significant enrichment for breakpoints within 1 Mb of a superenhancer in the MM1.s myeloma cell line and in CD19^+^ B cells (*P*=0.0049 and 0.041, respectively). No enrichment was seen with enhancer locations in K562 cells, CD3^+^ T cells or skeletal muscle myoblasts indicating a cell-specific enrichment for superenhancers in the B-cell lineage.

The partner loci to *MYC* are also mostly related to myeloma pathogenesis or B-cell biology ([Table 3](#tbl3){ref-type="table"}). In addition to the Ig loci, partner genes of *MYC* rearrangements included *FAM46C*, *KRAS* and *CCND1*. All of these genes are candidates in many genetic studies of myeloma. *FAM46C* is deleted in ∼20% of samples and mutated in ∼3% of samples.^[@bib2],\ [@bib25]^ *KRAS* is mutated in 31% of samples and *CCND1* is overexpressed in t(11;14) accounting for ∼15% of samples.^[@bib26],\ [@bib27]^ In addition, XBP1 is involved in plasma cell differentiation, the unfolded protein response and is mutated in a low percentage of relapsed refractory myeloma.^[@bib26],\ [@bib28]^ The genes located next to breakpoints in the remaining samples may also be active in B-cell biology or myeloma pathogenesis as recurrent translocations are found near the *CHST15* locus, which is known to be involved in B-cell signaling,^[@bib29],\ [@bib30]^ and *FOXO3,* which is involved in B-cell development.^[@bib31]^ Some rearrangements from these samples are shown in [Figure 2](#fig2){ref-type="fig"} to illustrate the colocalization of superenhancers to *MYC*.

Impact on MYC expression
------------------------

Previously published gene expression array data were available on 33 of the samples ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).^[@bib2]^ We categorized the samples according to the presence (*n*=9) or absence (*n*=24) of a *MYC* translocation, as detected by the capture assay, and used the *MYC* probe set (202431_s\_at) to examine any difference in expression between the groups. Those samples with any *MYC* translocation had higher expression of *MYC* compared with those without a translocation (median 703.2 vs 2313), but this did not reach significance with this number of samples (*P*=0.065) [Figure 3a](#fig3){ref-type="fig"}. This was extended in the full Myeloma IX data set for which any translocation was detected by FISH or capture and for which expression array data were available. In this larger data set, samples with any translocation (*n*=27) had a significantly higher expression of *MYC* (2003 vs 945.8, *P*=0.009) compared with those with no translocation (*n*=142), even allowing for those samples on which no capture had been performed (and may contain translocations not detected by FISH) ([Figure 3b](#fig3){ref-type="fig"}). The increase in expression of *MYC* is consistent with its deregulation being the central mechanism.

Impact on clinical outcome
--------------------------

A subset of patients (*n*=55) from the capture panel had taken part in the UK MRC Myeloma IX trial, so we performed an analysis of the impact of *MYC* translocations on survival. *MYC* translocations had a significant impact on OS and PFS in univariate analysis ([Table 3](#tbl3){ref-type="table"}), which carried over into multivariate analysis, resulting in a significant decrease in OS and PFS for patients with a *MYC* translocation ([Figure 4](#fig4){ref-type="fig"}).

Discussion
==========

Here, we have investigated the partner loci involved in rearrangements with 8q24, namely *MYC*. We analyzed presenting cases of myeloma characterized by a range of different primary *IGH* translocation events and found evidence of a *MYC* translocation in 21% of samples, making it the most frequent translocation in presenting myeloma cases.

Although FISH analysis of 8q24 rearrangements found no significant association with primary translocation groups, we did find an enrichment for samples with a *MYC* breakpoint in samples that had a t(14;16) and a depletion of samples with a t(4;14) or hyperdiploidy when screened by the sequence capture technique. Other studies using FISH agree with our FISH-based results in that it has been reported that rearrangements at the *MYC* locus show a similar prevalence in hyperdiploid and non-hyperdiploid tumors^[@bib1]^ or show some trend to being associated with t(4;14).^[@bib3]^ The discrepancy between our capture results and those determined by FISH may lie in the technique used to study the abnormality. One study used both FISH and mapping arrays to examine *MYC* breakpoints and found that 33% of breakpoints detected by array were not detected by routine FISH analysis.^[@bib17]^ Therefore, a higher resolution assay, such as genome sequencing, may identify more breakpoints and explain some of the discrepant results. However, care must be taken regarding the frequency of sequence capture translocations within the primary translocation groups owing to the bias in sample selection and the relatively small number of samples studied.

It is notable that all groups find *MYC* rearrangements to be complex, often involving many chromosomes. We only capture the region surrounding *MYC* and are not able to detect any rearrangements downstream on the partner chromosome, which could result in inversions, insertions or duplications of DNA segments. Whole-genome sequencing of samples will provide more complex and detailed information regarding the final composition of the genome in these samples.

The translocations at 8q24 results in overexpression of *MYC* due to the colocalization of active superenhancers in the partner loci. The obvious examples of this belong to the known active enhancers in the B-cell lineage, the Ig loci, but in addition to these a series of previously unknown partners have also been identified. A similar study in B-cell lymphomas identified non-immunoglobulin partners to *MYC* rearrangements and concluded that these are non-random processes that juxtapose *MYC* with genes involved in lymphomagenesis (namely *BCL6*, *PAX5* and *IKAROS*).^[@bib32]^ We have identified a different set of genes in this study and interestingly these genes are related to B-cell biology and myeloma pathogenesis. We hypothesize that in different diseases with *MYC* rearrangements there is a selection process, which results in active superenhancers from genes that are expressed in that cell type being placed near *MYC*. In all B-cell neoplasias these include the Ig loci, but in different B-cell subtypes the non-Ig loci differ to include those that are expressed in that cell type. In myeloma these non-Ig partner genes include *FAM46C*, *KRAS*, *XBP1* and *CCND1*. The other partner genes identified here, which have no known function in myeloma or plasma cells, are likely also to be important in plasma cell development or myeloma disease as they have active superenhancers that are sequestered by *MYC*.

Some of the loci identified have active superenhancers up to 22 Mb away from the breakpoint. These distal superenhancers may be responsible for *MYC* overexpression, but as these results are based solely on data from the MM1.s cell line^[@bib24]^ it may be that in different myeloma cell types an enhancer closer to the breakpoint is active, and it is this as yet unidentified superenhancer that is located near *MYC* in this patient. This argument is exemplified by the lack of a superenhancer at the *IGK* locus in MM1.s and can be explained as this cell line expresses the lambda light chain and not the kappa light chain.^[@bib33]^ Similar studies involving a large cohort of myeloma cell lines would give further insight into the complex nature of superenhancers in this disease.

As the mechanism of action for *MYC* overexpression is through the juxtaposition of superenhancers specific to each disease, it is possible that this unifying mechanism can be therapeutically targeted. Given that it has been shown that superenhancers can be disrupted using BET-bromodomain inhibitors, such as JQ1,^[@bib24]^ it makes patients with *MYC* rearrangements good candidates for treatment with this class of drugs. We show here that patients identified with a *MYC* translocation have a poor PFS and OS compared with those with no rearrangement. If these patients could be identified in advance they may benefit from treatment with this class of targeted drugs.
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###### 

Click here for additional data file.

![*MYC* locus breakpoints in myeloma. The locations of breakpoints are indicated by vertical lines corresponding in color to whether the partner chromosome belongs to an Ig loci (IGH@, IGK@ or IGL@; red) or a non-Ig locus (black). The genes and orientation are indicated according to their genomic location on chromosome 8. Arcs indicate the positions of two breakpoints found in one sample.](bcj201413f1){#fig1}

![*MYC* rearrangements result in superenhancer colocalization on the derivative chromosome. Superenhancer elements are colocated near to MYC from a t(1;8) (top) or a t(8;22) (middle and bottom) where the partner chromosome gene (*FAM46C*, *XBP1* and *IGL*, respectively) has a known function in myeloma or B-cell biology.](bcj201413f2){#fig2}

![Expression of *MYC* in samples with a breakpoint is higher than in those without a breakpoint. (**a**) Expression data from 33 samples with sequence capture-determined translocations for those samples with no breakpoint at 8q24 (normal) and for those with an identified breakpoint (split *MYC*). (**b**) Expression data from 169 samples with any translocation detected by capture or FISH. Whisker plots show the 10--90 percentiles.](bcj201413f3){#fig3}

![Progression-free survival (**a**) and Overall-free survival (**b**) in patients with a *MYC* breakpoint is significantly decreased compared with those without a breakpoint. PFS *P*=0.032, OS *P*=0.035. Data adjusted for confounding variables in Tables 4a, 4b and 4c.](bcj201413f4){#fig4}

###### Frequency of 8q24 abnormalities detected by FISH

  *8q Status*          *Translocation (Tx) group*                                             
  -------------------- ---------------------------- ------ ------ ------ ------ ------ ------ ------
  Normal               49                           74     4      17     6      294    20     90
  Gain                 7                            17     2      8      4      46     10     17
  Split                3                            10     0      2      2      40     1      5
  Del                  5                            0      0      0      0      4      1      14
  Total abnormal (%)   23.4                         26.7   33.3   37.0   50.0   23.2   37.5   28.5

Abbreviation: FISH, fluorescence *in situ* hybridization.

###### Incidence of 8q24 breakpoints in sequence-capture samples

  *Translocation*                    *Assayed (%)*   *With 8q24 breakpoint (% of group)*   P*-value*
  ---------------------------------- --------------- ------------------------------------- -----------
  t(4;14)                            13(12.5)        0(0)                                  0.031
  t(6;14)                            8(7.7)          1(12.5)                               NS
  t(11;14)                           28(26.9)        5(17.8)                               NS
  t(14;16)                           17(16.3)        11(64.7)                              \<0.001
  t(14;20)                           6(5.8)          1(16.6)                               NS
  HRD                                31(29.8)        3(9.6)                                0.037
  Other[a](#t2-fn2){ref-type="fn"}   1(0.9)          1(100)                                NS
  Total                              104             21                                     

Abbreviations: HRD, hyperdiploidy; NS, not significant.

This sample has a secondary t(7;14).

###### Genomic locations of *MYC* breakpoints

  Sample     *IGH translocation*              *1st Chr*              *1st breakpoint*   *Part of 1st chr positioned next to chromosome 8*   *1st Gene*[a](#t3-fn1){ref-type="fn"}    *Distance (bp) to MM1.s enhancer from breakpoint*   *Distance (bp) to MM1.s superenhancer from breakpoint*   *2*^*nd*^ *Chr*          *2*^*nd*^ *breakpoint*         *2*^*n*d^ *Gene*[a](#t3-fn1){ref-type="fn"}
  --------- --------------------- ---------------------------------- ------------------ --------------------------------------------------- --------------------------------------- --------------------------------------------------- -------------------------------------------------------- ----------------- -------------------------------------- ---------------------------------------------
  29               t(7;14)                      chr22                36779252           [Telomeric]{.ul}                                    *MYH9*                                                           0                                                     0                                   chr8                      129251475                *PVT1-CCDC26*
  29               t(7;14)                       chr6                7986298            Telomeric                                           *TXNDC5*                                                       8862                                                   8862                                 chr8                      129375213                *PVT1-CCDC26*
  176               None                         chr1                118246012          Telomeric                                           *FAM46C-GDAP2*                                                 16232                                                 16232                                 chr8                      129264632                *PVT1-CCDC26*
  222             t(14;16)                       chr2                64412927           [Centromeric]{.ul}                                  *LINC00309*                                                    3194                                                  450109                                chr8                      129064694                *PVT1*
  222             t(14;16)                       chr2                64468628           Telomeric                                           *LINC00309-LGALSL*                                             12603                                               169177716                               chr8                      129104714                *PVT1*
  471               None                        chr22                23071965           Telomeric                                           *IGL*                                                          5005                                                   5005                                 chr8                      128737937                *POU5F1B-MYC*
  475             t(14;16)                      chr12                25507375           Telomeric                                           *KRAS-IFLTD1*                                                  20015                                                18435462                               chr8                      129368991                *PVT1-CCDC26*
  478             t(11;14)                       chr2                77937177           Telomeric                                           *LRRTM4-SNAR-H*                                               2872963                                               13042429                               chr8         128896717[b](#t3-fn2){ref-type="fn"}  *MYC-PVT1*
  592             t(14;16)                      chr11                111195351          [Telomeric]{.ul}                                    *C11ORF93-MIR4491*                                             36912                                                 36912                                 chr8                      129247671                *PVT1-CCDC26*
  592             t(14;16)                      chr10                122670424          Centromeric                                         *MIR5694*                                                     1102347                                               10042441                               chr8                      129248430                *PVT1-CCDC26*
  673             t(14;16)         chr14[c](#t3-fn3){ref-type="fn"}  106119946          [Telomeric]{.ul}                                    *IGH*                                                          26346                                                 26346                                 chr8                      129209665                *PVT1-CCDC26*
  730               None                        chr22                41824373           [Centromeric]{.ul}                                  *TEF-TOB2*                                                     13346                                                3109392                                chr8                      129312555                *PVT1-CCDC26*
  730               None                        chr22                23280899           Centromeric                                         *IGL*                                                            0                                                     0                                   chr8                      129345574                *PVT1-CCDC26*
  984             t(14;16)                       chr2                89151255           [Centromeric]{.ul}                                  *IGKC*                                                         95671                                                2922643                                chr8                      129228289                *PVT1-CCDC26*
  984             t(14;16)                       chr2                89130434           Centromeric                                         *IGKC*                                                         34641                                                8060442                                chr8                      129254453                *PVT1-CCDC26*
  1112            t(11;14)                      chr11                69283791           Centromeric                                         *CCND1*                                                       131027                                                2226257                                chr8                      128427581                *POU5F1B-MYC*
  1112            t(11;14)                       chrX                146700223          Centromeric                                         *MIR510-FMR1-AS1*                                 NA [d](#t3-fn4){ref-type="fn"}                         NA [d](#t3-fn4){ref-type="fn"}                    chr8                      129075004                *PVT1*
  1310            t(14;16)         chr6[e](#t3-fn5){ref-type="fn"}   108911604          Telomeric                                           *FOXO3*                                                          0                                                     0                                   chr8                      128761005                *MYC-PVT1*
  1310            t(14;16)         chr6[e](#t3-fn5){ref-type="fn"}   108908007          [Centromeric]{.ul}                                  *FOXO3*                                                          0                                                     0                                   chr8                      129000293                *PVT1*
  11/088          t(14;16)                      chr10                125858805          [Telomeric]{.ul}                                    *CHST15-OAT*                                                     0                                                     0                                   chr8                      129235977                *PVT1-CCDC26*
  11/388          t(14;16)                      chr22                23307780           Centromeric                                         *IGL*                                                          5757                                                   5757                                 chr8                      128712616                *POU5F1B-MYC*
  11/625           t(6;14)                       chr6                41858885           Centromeric                                         *USP49 (near CCND3)*                                          377392                                                10585809                               chr8                      128244760                *PCAT1-POU5F1B*
  11/741          t(14;16)                      chr22                29210349           Telomeric                                           *XBP1-ZNRF3*                                                     0                                                     0                                   chr8                      128772206                *MYC-PVT1*
  11/741          t(14;16)                       chr2                134989574          [Centromeric]{.ul}                                  *MIR3679-MGAT5*                                                47048                                                22523506                               chr8                      128772558                *MYC-PVT1*
  214             t(14;20)                      chr22                23285257           Centromeric                                         *IGL*                                                            0                                                     0                                   chr8                      129214819                *PVT1-CCDC26*
  11/1212         t(14;16)                      chr22                23258401           Centromeric                                         *IGL*                                                          9496                                                   9496                                 chr8                      129301246                *PVT1-CCDC26*
  11/1227         t(11;14)                      chr14                105969653          Telomeric                                           *MIR548AS-DAOA-AS1*                                            24389                                                 55470                                 chr8                      128504864                *POU5F1B-MYC*
  12/0213         t(11;14)                       chr1                118302879          Telomeric                                           *FAM46C-GDAP2*                                                   0                                                   73103                                 chr8                      128866931                *MYC-PVT1*
  12/0365         t(14;16)                      chr10                125858805          [Telomeric]{.ul}                                    *CHST15-OAT*                                                     0                                                     0                                   chr8                      129235977                *PVT1-CCDC26*
  12/0365         t(14;16)                      chr17                74521561           Centromeric                                         *RHBDF2-CYGB*                                                  30899                                                 645847                                chr8                      129262577                *PVT1-CCDC26*
  12/0404         t(11;14)                      chr11                69425933           Centromeric                                         *MYEOV-CCND1*                                                  32171                                                2368440                                chr8                      128719531                *POU5F1B-MYC*

Where \>1 gene is named, the breakpoint is in the intergenic space between genes.

Breakpoint within inversion.

Confirmed by FISH.

Complex rearrangement containing 400 bp of chrX with translocations leading to chromosomes 14 (IGH@) and 8 (PVT1) as well as a t(8;11) and t(11;14).

Confirmed by karyotype underlined=derivative does not contain MYC.

###### Clinical characteristics of MYC-translocated samples

  Variable                                                         *Number of patients*   *PFS*   *OS*             
  ---------------------------------------------------------------- ---------------------- ------- --------- ------ ---------
  MYC translocation                                                14                     11.8    0.016     19.7   0.043
  No MYC translocation                                             41                     20.0              55.8    
  t(14;16)                                                         9                      9.0     0.006     11.2   0.095
  No t(14;16)                                                      46                     20.0              47.7    
  Adverse *IGH* translocation                                      27                     13.4    0.018     25.5   0.021
  No adverse *IGH* translocation                                   28                     24.8              61.7    
  ISS 1                                                            7                      61.9    0.013     NR     0.018
  ISS 2                                                            15                     23.9              60.4    
  ISS 3                                                            16                     13.8              27.6    
  Eligible for intensive pathway[a](#t4a-fn3){ref-type="fn"}       36                     25.3    \<0.001   80.0   \<0.001
  Not eligible for intensive pathway[a](#t4a-fn3){ref-type="fn"}   19                     11.8              23.4    

Abbreviations: OS, overall survival; PFS, progression-free survival.

Univariate analysis---statistically significant.

Patients treated according to the intensive pathway received autologous stem cell transplantation, whereas patients not eligible entered the non-intensive pathway and were treated only with attenuated doses of chemotherapy.

###### Multivariate analysis of variables significantly associated with an improved PFS

  *Variable*                         P*-value*   *Hazard ratio*   *95% CI*
  ---------------------------------- ----------- ---------------- ---------------
  Absence of adverse translocation   0.03        2.763            1.105--6.908
  Absence of MYC translocation       0.035       3.094            1.081--8.856
  Treatment on the intensive path    \<0.001     5.871            2.186--15.766

Abbreviations: CI, confidence interval; PFS, progression-free survival.

###### Multivariate analysis of variables significantly associated with an improved OS

  *Variable*                         P*-value*   *Hazard ratio*   *95% CI*
  ---------------------------------- ----------- ---------------- ---------------
  Absence of adverse translocation   0.010       4.861            1.450--16.293
  Absence of MYC translocation       0.032       4.077            1.125--14.785
  Treatment on the intensive path    0.001       6.528            2.196--19.404

Abbreviations: CI, confidence interval; OS, overall survival.
